Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 07, 2024 at 07:30 am EST
Share
Alimera Sciences, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 26.31 million compared to USD 14.03 million a year ago. Net loss was USD 3.78 million compared to USD 3.78 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.54 a year ago.
For the full year, the company reported sales was USD 80.75 million compared to USD 54.13 million a year ago. Net loss was USD 20.13 million compared to USD 18.11 million a year ago.
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.